Blood Res.  2019 Dec;54(4):284-285. 10.5045/br.2019.54.4.284.

Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria

• Song IC
• Choi YS
• Shin JW
• Song HJ
• Kim J
• Jo DY

• KMID: 2466595
• DOI: http://doi.org/10.5045/br.2019.54.4.284

Abstract

No abstract available.

MeSH Terms

Cerebral Infarction*
Global Health*
Humans
Mass Screening*
Retrospective Studies*
World Health Organization*

Reference

1. Kaifie A, Kirschner M, Wolf D, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016; 9:18.

2. Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep. 2017; 12:389–396.

3. Enblom A, Lindskog E, Hasselbalch H, et al. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. 2015; 26:344–347.

4. Ong E, Barraco F, Nighoghossian N, et al. Cerebrovascular events as presenting manifestations of myeloproliferative neoplasm. Rev Neurol (Paris). 2016; 172:703–708.

5. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127:2391–2405.

6. GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018; 379:2429–2437.

7. Hong KS, Bang OY, Kang DW, et al. Stroke statistics in Korea: part I. Epidemiology and risk factors: a report from the Korean Stroke Society and clinical research center for stroke. J Stroke. 2013; 15:2–20.